GERON CORP — fact timeline

GERON CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-20 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, based upon the following votes:”

GERON CORP shareholders approved Non-binding advisory vote on named executive officer compensation at the 2026-05-20 meeting.

“The Company’s stockholders approved the non-binding, advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the 2026 Proxy Statement, based upon the following votes:”

GERON CORP shareholders approved Amendment to the 2018 Equity Incentive Plan to increase shares by 4,500,000 at the 2026-05-20 meeting.

“The Company’s stockholders approved the amendment to the Company’s 2018 Equity Incentive Plan to, among other items, increase the number of shares of the Company’s common stock issuable thereunder by 4,500,000 shares, based upon the following votes:”

GERON CORP shareholders approved Election of Class III Directors at the 2026-05-20 meeting.

“The Company’s stockholders elected each of the three (3) nominees to hold office as Class III directors to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier resignation or removal.”

GERON CORP amended First Amendment to Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership valued at Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3 (effective 2026-01-05).

“On January 5, 2026, Geron Corporation ("we" or the "Company") entered into that certain first amendment to loan agreement (the "First Amendment Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a "Lender"), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the "Agent"), which amends the terms of that certain Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement", and as amended by the First Amendment Agreement, the "Amended Loan Agreement), by and among the Company, the Lenders and the Agent.”

GERON CORP announced a restructuring with charges of approximately $18 million affecting the entire company (approximately one-third of its current approximately 260 employees).

“affected employees on December 16, 2025, and expects the RIF to be substantially complete in the first quarter of 2026. The Company estimates that it will incur approximately $18 million in restructuring and restructuring-related charges, consisting primarily of one-time employee severance payments, healthcare and related benefits, and other employee-related”

Elizabeth G. O'Farrell was appointed as Chair of the Board at GERON CORP.

“In addition, effective March 10, 2025, Ms. Elizabeth G. O’Farrell, currently the Lead Independent Director of the Board, was appointed Chair of the Board.”

Dawn C. Bir was appointed as Interim President and Chief Executive Officer at GERON CORP.

“Also, effective March 10, 2025, Dawn C. Bir, a current member of the Board, was appointed as the Interim President and Chief Executive Officer of Geron”

John A. Scarlett resigned as President, Chief Executive Officer and Chairman at GERON CORP.

“Effective March 10, 2025, the service of John A. Scarlett, M.D. as the President, Chief Executive Officer and Chairman of the Board of Directors (the “Board”) of Geron Corporation (the “Company” or “Geron”) concluded and, in connection therewith, Dr. Scarlett resigned from the Board.”

Elizabeth G. O'Farrell was appointed as Chair of the Board at GERON CORP.

“In addition, effective March 10, 2025, Ms. Elizabeth G. O'Farrell, currently the Lead Independent Director of the Board, was appointed Chair of the Board.”

Dawn C. Bir was appointed as Interim President and Chief Executive Officer at GERON CORP.

“Also, effective March 10, 2025, Dawn C. Bir, a current member of the Board, was appointed as the Interim President and Chief Executive Officer of Geron to serve in such capacity while the Company conducts a search for a permanent Chief Executive Officer.”

GERON CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 at the 2024-05-09 meeting.

“The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 420,096,104 3,227,292 691,320 N/A”

GERON CORP shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2024-05-09 meeting.

“The non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the 2024 Proxy Statement was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 272,059,071 8,999,145 1,941,720 141,014,780”

GERON CORP shareholders approved Election of three Class I directors at the 2024-05-09 meeting.

“Each of the three (3) nominees to hold office as Class I members of the Board of Directors to serve for a three-year term expiring at the Company’s 2027 annual meeting of stockholders were elected based upon the following votes: Name of Director Nominee Votes In Favor Votes Withheld Broker Non-Votes John F. McDonald 277,269,957 5,729,979 141,014,780 John A. Scarlett, M.D. Robert J. Spiegel, M.D., FACP 275,707,115 243,088,760 7,292,821 39,911,176 141,014,780 141,014,780”

GERON CORP entered into Underwriting Agreement with Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated valued at approximately $150.0 million (effective 2024-03-19).

“On March 19, 2024, Geron Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 41,999,998 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 8,002,668 shares of Common Stock (the “Pre-Funded Warrants”).”

GERON CORP reported the fourth quarter and full year 2023 results: revenue $23,000 and $237,000, respectively.

“loan facility, will be sufficient to fund its projected operating expenses into the third quarter of 2025. Revenues for the three and twelve months ended December 31, 2023, were $23,000 and $237,000, respectively, compared to $103,000 and $596,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of”

GERON CORP: Amended and restated bylaws to reflect statutory changes under Delaware law, clarify language, incorporate SEC rule changes, enhance advance notice provisions, and reflect current public company practices (effective 2023-12-14).

“On December 14, 2023, the Board of Directors (the “Board”) of the Company, upon recommendation of the Nominating and Corporate Governance Committee of the Board, approved the amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Bylaws”), which had not been amended since 2010, to, among other things, reflect statutory changes under Delaware law, clarify and simplify language in certain provisions, incorporate rule changes from the Securities and Exchange Commission, enhance the advance notice provisions, and reflect current practices among public companies.”

GERON CORP incurred term loan of $30,000,000 with Silicon Valley Bank and Hercules Capital Inc. at the greater of: (x) 9.0%, or (y) the sum of (A) the Prime Rate (as reported in T.

“tranches, subject to certain terms and conditions. The Amended Loan Agreement also provides that (i) the fourth tranche of the Term Loan has been increased from $10,000,000 to $30,000,000, (ii) the commitment period for the fifth tranche of the Term Loan of $20 million, which is available subject to achievement of a regulatory milestone and satisfaction of certain”

GERON CORP amended Third Amendment to Loan and Security Agreement with Silicon Valley Bank and Hercules Capital Inc. valued at $125 million (effective 2023-12-14).

“On December 14, 2023 (the “Amendment Effective Date”), Geron Corporation (“Geron” or the “Company”) amended its existing term loan facility with Silicon Valley Bank and Hercules Capital Inc. as lenders (the “Lenders”) and Hercules Capital Inc. as administrative agent and collateral agent for the Lenders pursuant to a Third Amendment to Loan and Security Agreement (the “Third Amendment,” and the existing Loan and Security Agreement as amended, the “Amended Loan Agreement”) by and among the Company, the Lenders and the Agent.”

Gaurav Aggarwal was appointed as Director at GERON CORP.

“appointed Gaurav Aggarwal, M.D. to the Board, effective immediately, as a Class III Board member with a term expiring at the Company’s 2026 annual meeting of stockholders.”

GERON CORP reported three and nine months ended September 30, 2023 results: revenue $164,000 and $214,000, respectively.

“loan facility, will be sufficient to fund its projected operating requirements through the end of Q3 2025. Revenues for the three and nine months ended September 30, 2023, were $164,000 and $214,000, respectively, compared to $297,000 and $493,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of”

GERON CORP entered into 2023 Sales Agreement with B. Riley Securities, Inc. valued at up to $100 million (effective 2023-11-01).

“On November 1, 2023, Geron Corporation (the “Company”) entered into an At Market Issuance Sales Agreement (the “2023 Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley Securities”), pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through B. Riley Securities as its sales agent.”

Olivia K. Bloom departed as Chief Financial Officer and Treasurer at GERON CORP.

“On September 11, 2023, Geron Corporation (“Geron” or the “Company”) announced the appointment of Michelle J. Robertson as Executive Vice President, Chief Financial Officer and Treasurer, effective September 25, 2023, succeeding Olivia K. Bloom, who will retire from that role with the Company on that date.”

Michelle J. Robertson was appointed as Executive Vice President, Chief Financial Officer and Treasurer at GERON CORP.

“On September 11, 2023, Geron Corporation (“Geron” or the “Company”) announced the appointment of Michelle J. Robertson as Executive Vice President, Chief Financial Officer and Treasurer, effective September 25, 2023, succeeding Olivia K. Bloom, who will retire from that role with the Company on that date.”

GERON CORP reported the three and six months ended June 30, 2023 results: revenue $29,000 and $50,000, respectively.

“to fund its projected operating requirements through the end of 2025. Second Quarter 2023 Financial Results Revenues for the three and six months ended June 30, 2023, were $29,000 and $50,000, respectively, compared to $73,000 and $196,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of cell-based”

GERON CORP: Amendment to Restated Certificate of Incorporation to increase authorized common stock from 675,000,000 to 1,350,000,000 shares (effective 2023-05-31).

“At the 2023 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 675,000,000 to 1,350,000,000 shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of Amendment of the Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on May 31, 2023 and was effective as of such date.”

GERON CORP shareholders approved Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-02 meeting.

“The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 388,960,314 3,261,710 1,126,380 N/A”

GERON CORP shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the 2023 Proxy Statement. at the 2023-06-02 meeting.

“The non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the 2023 Proxy Statement was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 288,241,915 22,529,801 2,231,511 80,345,177”

GERON CORP shareholders approved Non-binding advisory vote on the preferred frequency of holding future advisory votes on executive compensation. at the 2023-06-02 meeting.

“The non-binding advisory vote on the preferred frequency of holding future advisory votes on executive compensation selected Every One Year based upon the following votes: Every One Year Every Two Years Every Three Years Abstentions 301,573,387 1,471,320 5,369,217 4,589,303”

GERON CORP shareholders approved Amendments to the 2018 Equity Incentive Plan to increase the total number of shares of Common Stock issuable thereunder by 43,360,000 shares and modify the fungible plan design. at the 2023-06-02 meeting.

“The amendments to our 2018 Equity Incentive Plan to, among other items, increase the total number of shares of Common Stock issuable thereunder by 43,360,000 shares and modify the fungible plan design were approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 281,362,072 30,179,338 1,461,817 80,345,177”

GERON CORP shareholders approved Amendment to the Company’s Restated Certificate of Incorporation to increase the total number of authorized shares of Common Stock from 675,000,000 to 1,350,000,000 shares. at the 2023-06-02 meeting.

“The amendment to the Company’s Restated Certificate of Incorporation to increase the total number of authorized shares of our Common Stock from 675,000,000 to 1,350,000,000 shares hereby was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 289,421,270 23,154,706 427,251 80,345,177”

GERON CORP shareholders approved Election of Class III directors to serve for a three-year term expiring at the Company's 2026 annual meeting. at the 2023-06-02 meeting.

“Each of the two (2) nominees to hold office as Class III members of the Board of Directors to serve for a three-year term expiring at the Company’s 2026 annual meeting of stockholders were elected based upon the following votes: Name of Director Nominee Votes In Favor Votes Withheld Broker Non-Votes V. Bryan Lawlis 287,975,430 25,027,797 80,345,177 Susan M. Molineaux 245,618,904 67,384,323 80,345,177”

GERON CORP reported the first quarter of 2023 results: revenue $21,000, net income $38.1 million, or $0.07 per share, EPS $0.07 per share. Guidance reaffirmed.

“a net loss of $38.1 million, or $0.07 per share, compared to $30.1 million, or $0.09 per share, for the first quarter of 2022. Revenues for the first quarter of 2023 were $21,000 compared to $123,000 for the same period in 2022. Royalty revenues in 2023 and 2022 primarily reflect estimated royalties from sales of cell-based research products from the”

Karin Eastham retired as Director at GERON CORP.

“On February 22, 2023, Karin Eastham, a Class III member of the Company’s Board, notified the Board of her retirement from the Company’s Board after 13 years of service on the Company’s Board and imetelstat’s achievement of positive top-line results in the IMerge Phase 3 trial in lower risk myelodysplastic syndromes.”

GERON CORP entered into Underwriting Agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein valued at $198.1 million (effective 2023-01-05).

“On January 5, 2023, Geron Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 55,876,297 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 25,000,000 shares of Common Stock (the “Pre-Funded Warrants”).”

GERON CORP reported the three and nine months ended September 30, 2022 results: revenue $297,000 and $493,000, respectively, net income net loss of $41.1 million, or $0.10 per share, EPS $0.10 per share.

“For the third quarter of 2022, the Company reported a net loss of $41.1 million, or $0.10 per share, compared to $26.7 million, or $0.08 per share, for the comparable 2021 period. Net loss for the first nine months of 2022 was $99.3 million, or $0.26 per share, compared to $84.1 million, or $0.26 per share, for the comparable 2021 period. Revenues for the three and nine months ended September 30, 2022, were $297,000 and $493,000, respectively, compared to $109,000 and $353,000 for the comparable 2021 periods.”

John F. McDonald was appointed as Director at GERON CORP.

“appointed John F. McDonald to the Board, effective immediately, as a Class I Board member”

Faye Feller was appointed as Executive Vice President and Chief Medical Officer at GERON CORP.

“Effective as of July 9, 2022, Faye Feller, M.D., will assume the duties and responsibilities of Executive Vice President and Chief Medical Officer of the Company.”

Aleksandra Rizo resigned as Executive Vice President and Chief Medical Officer at GERON CORP.

“On June 9, 2022, Aleksandra Rizo, M.D., Ph.D., notified Geron Corporation (the “Company” or “Geron”) of her decision to resign from her position as Executive Vice President and Chief Medical Officer of the Company, with her last day of employment being July 8, 2022”

Melissa Kelly Behrs was appointed as Executive Vice President, Business Operations, and Chief Alliance Officer at GERON CORP.

“In connection with Mr. Koval’s appointment as Chief Business Officer, Ms. Kelly Behrs has been appointed Executive Vice President, Business Operations, and Chief Alliance Officer.”

Edward Koval was appointed as Executive Vice President and Chief Business Officer at GERON CORP.

“On December 1, 2021, the Board of Directors (the “Board”) of Geron Corporation (the “Company”) appointed Edward Koval as the Company’s Executive Vice President and Chief Business Officer.”